Intuitive Surgical Intrinsic Value Calculation – INTUITIVE SURGICAL Reports 14.6% Decrease in Revenue for FY2022 Q4, But 6.7% Increase in Net Income.

Earnings report

Intuitive Surgical Intrinsic Value Calculation – INTUITIVE SURGICAL ($NASDAQ:ISRG), a publicly-traded healthcare technology company, recently announced their earnings results for the fourth quarter of FY2022, which ended on December 31, 2022. The company reported total revenue of USD 324.9 million, a 14.6% decrease compared to the same quarter of the year prior. Despite this decline, their reported net income saw a 6.7% rise year over year, to USD 1655.0 million. The company is best known for its da Vinci Surgical System, which is a robotic-assisted surgical system that enables surgeons to perform minimally invasive surgeries in the specialties of urology, gynecology, and general surgery. The da Vinci Surgical System has become increasingly popular among surgeons due to its ability to reduce the risk of post-operative complications, improve patient recovery times, and reduce overall healthcare costs. INTUITIVE SURGICAL is also leveraging its technology to develop new products and services, such as its Intuitive Passport platform. This platform provides surgeons with access to real-time data on patient outcomes and helps to streamline the entire surgical process.

Additionally, the company has partnered with other leading healthcare companies such as Johnson & Johnson and Novartis to expand their reach and develop new solutions for the healthcare industry. Despite the 14.6% decrease in revenue during Q4 of FY2022, INTUITIVE SURGICAL remains confident in their business model and ability to generate long-term growth. Despite the challenges posed by the pandemic, the company has managed to increase its net income by 6.7%. This is due in part to the company’s continued focus on innovation, as well as its strategic partnerships with other industry leaders. Overall, INTUITIVE SURGICAL’s Q4 earnings report shows that the company is still well-positioned to capitalize on new opportunities within the healthcare industry. With their continued focus on innovation and strategic partnerships, the company is set to be a major player in the healthcare sector for years to come.

Price History

On Tuesday, INTUITIVE SURGICAL reported a 14.6% decrease in revenue for the fourth quarter of fiscal year 2022. Despite this decrease, the company’s net income saw a 6.7% increase compared to the same period last year. The company’s stock opened the day at $254.6 and closed at $258.0, up by 0.8% from its previous closing price of $256.0. This decrease in revenue could be attributed to the challenging times caused by the coronavirus pandemic and its effects on the global economy.

However, the company’s net income still saw a 6.7% increase due to its efforts in cost-cutting and streamlining of operations. The company’s stock performance was also promising, as it opened at $254.6 and closed at $258.0, a 0.8% increase from its closing price the day before. INTUITIVE SURGICAL is a medical technology company that designs, manufactures, and markets robotic systems for surgical procedures. Their products are used in various medical fields such as general surgery, gynecology, urology, and head and neck surgery. They are well-known for their da Vinci Surgical System, which is used to perform minimally invasive surgeries. The company has seen success in its operations despite the economic uncertainty due to the pandemic. With their efforts to reduce costs and streamline operations, they have been able to maintain their net income and increase their stock performance this quarter. While their revenue has decreased in the short-term, it is likely to rebound once the economy stabilizes and the pandemic subsides. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Intuitive Surgical. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Intuitive Surgical. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Intuitive Surgical. More…

Key Ratios Snapshot

Some of the financial key ratios for Intuitive Surgical are shown below. More…

Analysis – Intuitive Surgical Intrinsic Value Calculation

GoodWhale has conducted an analysis of INTUITIVE SURGICAL‘s wellbeing and found that the intrinsic value of INTUITIVE SURGICAL share is around $298.6, calculated by our proprietary Valuation Line. The current market price of the stock is $258.0, indicating that INTUITIVE SURGICAL is currently undervalued by 13.6%. This suggests that investors should consider buying INTUITIVE SURGICAL stock at this price, as it could yield a good return on investment. The company has a strong track record of delivering innovative products and services, which has enabled it to establish a significant presence in its field. It is well-positioned to benefit from any upturns in the sector, so investors should take advantage of its current undervaluation. The analysis also found that INTUITIVE SURGICAL has a strong balance sheet, with healthy cash flow and low levels of debt. This indicates that the company is well-positioned to weather any downturns in the sector and continue its current rate of growth. Furthermore, the company has a strong reputation for customer service and satisfaction, which will be beneficial in the long-term. Overall, GoodWhale’s analysis shows that INTUITIVE SURGICAL is currently undervalued and could make a good investment for those looking to take advantage of this opportunity. However, as with any investment decision, investors should consider their own financial goals and risk tolerance before making any decisions. More…

Peers

The company’s da Vinci surgical system consists of a surgeon’s console, a patient-side cart and a vision system. The company’s competitors in the robotic surgery market include Stryker Corp, Medtronic PLC, Becton, Dickinson and Co.

– Stryker Corp ($NYSE:SYK)

With a market capitalization of $84.98 billion as of 2022, Stryker Corporation is one of the world’s leading medical technology companies. Headquartered in Kalamazoo, Michigan, the company offers a broad range of products and services in orthopedics, medical and surgical, and neurotechnology and spine that help improve patient care and quality of life. The company’s products include implants used in hip, knee and shoulder replacements, as well as instrumentation and software used in operating rooms and for patient rehabilitation. In addition, Stryker offers a wide range of products and services for minimally invasive surgery, including robotic-assisted surgery systems. The company’s return on equity was 10.79% as of 2022.

– Medtronic PLC ($NYSE:MDT)

Medtronic PLC is a medical technology company that develops and produces a variety of medical devices and software products. The company has a market capitalization of 112.31 billion as of 2022 and a return on equity of 7.49%. Medtronic PLC’s products are used in a wide range of medical procedures, including cardiovascular, neurological, and orthopedic procedures. The company’s products are sold in over 150 countries around the world.

– Becton, Dickinson and Co ($NYSE:BDX)

Becton, Dickinson and Co is a medical technology company that manufactures and sells medical devices, laboratory equipment, and diagnostic products. The company has a market cap of 64.37B as of 2022 and a return on equity of 6.42%. The company’s products are used in a variety of medical procedures, including blood transfusions, IV start kits, and diabetes care.

Summary

INTUITIVE SURGICAL reported their earnings results for the fourth quarter of FY2022, showing a decrease in revenue of 14.6% year over year to USD 324.9 million. Despite this, net income rose by 6.7% to USD 1655 million, indicating that the company is still performing well. This is a positive sign for potential investors, as it indicates that the company is continuing to be profitable despite the setbacks caused by the pandemic. Investing in INTUITIVE SURGICAL could be a wise decision for those looking for long-term returns. The company has a strong history of success and has shown stability throughout the pandemic. Furthermore, their diverse product portfolio and customer base provide a solid foundation for growth in the future.

In addition, the company has been investing in research and development to further enhance their existing products and services. This initiative should help them to remain competitive in the industry and create further opportunities for investors. Overall, investing in INTUITIVE SURGICAL may be a good choice for those looking for a reliable and profitable long-term investment. The company has demonstrated its ability to adapt to changing market conditions and their focus on research and development should help them stay ahead of their competitors. Therefore, investors may want to consider adding INTUITIVE SURGICAL to their portfolio.